Public policy coverage and access to medicines in Brazil

Ricardo Montes de Moraes1, Maria Angelica Borges dos Santos2, Fabiola Sulpino Vieira3, Rosimary Terezinha de Almeida4

1 Instituto Brasileiro de Geografia e Estatística. Rio de Janeiro, RJ, Brasil
2 Universidade Federal do Rio de Janeiro. Instituto Alberto Luiz Coimbra de Pós-Graduação e Pesquisa em Engenharia. Programa de Engenharia Biomédica. Rio de Janeiro, RJ, Brasil
3 Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública. Rio de Janeiro, RJ, Brasil
4 Instituto de Pesquisa Econômica Aplicada. Brasília, DF, Brasil

ABSTRACT

OBJECTIVE: Describe consumption patterns for monetary and non-monetary acquisition of medicines according to age and income groups, highlighting pharmaceuticals associated with health programs with specific access guarantees.

METHODS: Descriptive observational study using microdata from the 2017–2018 Pesquisa de Orçamentos Familiares (Household Budget Survey, POF/IBGE). We initially reviewed programs/policies with specific guarantees of access to medicines in the SUS. Using the pharmaceutical product list of POF-4 (chart 29 of the questionnaire on individual expenditures), we selected the medicines related to these programs. We then described frequencies and percentages for not reporting medicine consumption and for reporting consumption (either through monetary or non-monetary acquisition) according to age and income groups. For medicines with distinctive access guarantees, we compared average monthly values of acquisitions and consumption patterns by age and income.

RESULTS: 63% of those in the ≤ 2 minimum wage (MW) household income group did not report consuming medicines in the last month. Among those earning > 25 MW, 44.3% did not report consumption. Non-monetary acquisitions of medicines were mainly reported for the < 10 MW group and for the elderly and accounted for 20.5% of the total consumption of medicines (in value). For policies with specific access guarantees, non-monetary acquisitions reached 33.6% of total consumption. This percentage varied for the various selected medicines: vaccines, 83.3%; cancer drugs, 70.3%; diabetes, 47.9%; hypertension, 35.9%; asthma and bronchitis, 29.2%; eye problems, 14%; prostate and urinary tract, 10.7%; gynecological, 11.6%; and contraceptives, 9.7%.

CONCLUSION: Shares for non-monetary acquisitions of medicines are still low but benefit mainly lower-income and older age groups. Policies and programs with specific access guarantees to medicines have increased access. Results suggest the need to strengthen and expand pharmaceutical care policies.

DESCRIPTORS: Health Services Accessibility. National Policy of Pharmaceutical Assistance. Drugs of Continuous Use. Drugs, Essential. Program Evaluation.
INTRODUCTION

Pharmaceuticals are a significant component of the global health spending. Among Organization for Economic Cooperation and Development (OECD) member countries, they account for 20% of total health expenditures. In Brazil, they account for 18.4% of the country’s expenditures on health goods and services, and for 29.2% of household health expenditures, especially compromising the most vulnerable. This highlights the importance of public funding in access to medicines.

Public policies on pharmaceutical coverage are defined according to their breadth, scope, and depth (whether copayment is required to obtain medicines). Pharmaceutical market regulatory and pricing policies determine expenditures incurred by households and, ultimately, their access to medicines.

The breadth of pharmaceutical coverage defines the percentage of the population having access via public funding. OECD countries usually provide comprehensive coverage for medicines through government reimbursement schemes or specific insurance schemes. Restrictions concern the scope of medicines available (positive and negative lists for government funding) and whether copayment is required. Emerging countries, on the other hand, do not provide full public coverage. In practice, they restrict public funding to specific demographic or population segments or diseases, with a limited scope of medicines available.

In Brazil, the Política Nacional de Medicamentos (PNM – National Medicine Policy) and the Política Nacional de Assistência Farmacêutica (PNAF – National Pharmaceutical Care Policy), issued in 1998 and 2004, respectively, established guidelines and strategic axes to secure access to medicines and to promote their rational use. They also defined the Relação Nacional de Medicamentos Essenciais (Rename – National List of Essential Medicines). As of 2012, the Rename lost its role in guiding public supply of medicines and started being considered a positive list for public funding by the three spheres of government.

In addition to the expectation of securing access to medicines in the Rename, the Brazilian National Health System (SUS) has organized its pharmaceutical care (PC) around several programs and policies targeting specific population segments or diseases. These include, in variably explicit ways, distinctive guarantees of access to medicines. Mapping the policies that provide these distinctive guarantees is a good starting point to monitor performance in this area.

Nationwide studies on the extent of pharmaceutical coverage in Brazil are scarce. Data on public procurement may be obtained from government administrative records and used to produce information on the availability of medicines. There are significant gaps in these data, notably regarding purchases by states and municipalities. In addition, data lack information on the scope and population coverage by the PC policies.

The Pesquisa de Orçamentos Familiares (POF – Household Budget Survey) is an infrequently used source that may allow us to obtain more details on coverage by type of medicine, beneficiary and consumption (divided into monetary and non-monetary acquisitions). In addition to reporting out of pocket (OOP) expenditures on pharmaceuticals (monetary acquisitions), the POF asks respondents to estimate the monetary values of medicines obtained as non-monetary acquisitions. This provides potential information on public funding for medicines. The POF also allows us to describe the distribution of consumption by income and age groups, both for monetary and non-monetary acquisitions.

Starting by systematizing SUS programs and policies containing explicit PC guarantees, we sought to identify patterns of coverage and consumption for non-monetary acquisition by income and age groups. Understanding who benefits from non-monetary acquisitions is crucial to monitor and evaluate policy results in this area.
**METHODS**

This is an observational study using data from the *Pesquisa de Orçamentos Familiares* (POF) of the *Instituto Brasileiro de Geografia e Estatística* (IBGE – Brazilian Institute of Geography and Statistics). We initially reviewed the Health Legislation for laws, ordinances and norms related to health programs specifically including the provision of medicines among their objectives. We then went on to identify the main current specific guarantees of access to pharmaceutical coverage in the SUS.

The POF is a household survey with a sample of 57,920 households selected in conglomerates at the different strata of the survey. It has national representativeness and aims to describe the consumption and income patterns, as well as the living conditions of Brazilian households. Using the variables in chart 29 of the POF’s individual expenditure questionnaire (Questionnaire 4), comprising 88 types of pharmaceutical products, we prepared translators to associate each of the previously identified programs with the corresponding POF’s types of pharmaceutical products. Two authors - a physician and a pharmacist - selected and matched the pharmaceutical product types to the related PC programs. Both authors were seasoned in public health management.

We used the latest edition of the POF, covering from July 11, 2017 to July 9, 2018. Data on pharmaceutical products in the survey refer to those obtained in the 30 days preceding the interview.

The survey provides data on consumption expenditures and mode of acquisition (variable \(V9002\)), divided into ‘monetary acquisition’ and ‘non-monetary acquisition’ (without OOP payment by those obtaining the medicine). For the non-monetary acquisitions, respondents also report their estimated values for the medicines obtained. The POF microdata also include deflated values for the January 2018 reference period (variable \(V8000\_defla\)) to prevent price variations over the data collection period from distorting the interpretation of results.

For each type of pharmaceutical product listed in the POF, the number of people reporting consumption and the reported values for monetary and non-monetary acquisitions were aggregated according to age (\(V0403\)) and income groups (variable *Renda_total (Total_household_income)* for those obtaining the medicine).

Aggregation by age groups covers 14 age ranges from 0–19 years-old to > 80 years-old, at five or ten-year intervals. Aggregations by income include seven ranges: ≤ two minimum wages (MW), 2–3 MW, 3–6 MW, 6–10 MW, 10–15 MW, 15–25 MW, and > 25 MW.

To check the consistency between values estimated by respondents for non-monetary acquisitions and those informed for monetary acquisitions (proxy of market prices), we calculated the average monthly values for monetary and non-monetary acquisitions for each type of pharmaceutical product.

A descriptive analysis, with one-off and interval-based estimates, was carried out for:
(a) average monthly values and percentages of subjects reporting consumption; (b) total consumption of medicines; (c) percentage of subjects reporting non-monetary acquisitions among those obtaining medicines from programs with specific guarantees of access.

Variables with small frequencies in the sample were excluded from tables. Analyses were performed using the *R* software (version 4.0.3), and the *survey* package (version 4.0), which considers the sampling design of the survey. The share of subjects reporting non-monetary acquisition in total consumption was described by age and income groups. We used the *svyciprop* function to calculate 95% confidence intervals.

**RESULTS**

Brazil has several health programs or policies involving specific guarantees of access to medicines. In addition to the PNM and the PNAF, which are more comprehensive, we identified those policies and programs and related them to the specific types of pharmaceutical products surveyed in the POF (Box).
When considering the universe of pharmaceutical products with data collected in the POF (and not just those with specific guarantees of access in the SUS), 63% of the ≤ 2 MWs household income group did not report obtaining medicines in the last month. In the > 25 MWs group, this percentage was 44.3% (Figure). Consumption percentages decrease along income groups, suggesting budgetary restrictions to consumption in lower income groups and/or excessive consumption in higher income groups.

Subjects earning < 10 MWs have the greatest shares of non-monetary acquisitions. Nevertheless, shares for non-monetary acquisitions are low across all income groups, varying from 5.8% to 17.9% for exclusively non-monetary acquisition (Figure).

Starting from the 2–3 MWs group, non-monetary acquisitions - including the ‘both monetary and non-monetary acquisition’ category depicted in Figure - decrease as income increases. The lowest share for this compound non-monetary acquisitions is seen in the > 25 MWs group (4.5%). For the ≤ 2 MWs group, this percentage is 9.9%.

**Box. Specific guarantees of access to medicines in health policies and programs, according to POF types of pharmaceutical products.**

| Policies/Programs                                                                 | Specific guarantees of access to medicines                                                                 | POF pharmaceutical product type                  |
|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| Política Nacional de Atenção em Oftalmologia (National Eye Care Policy)         | Pharmaceutical Care in SUS as a policy issue, focusing on glaucoma treatment. Medicines included in the  | For eye disorders (ophthalmology)                 |
|                                                                                | Componente Especializado da Assistência Farmacêutica (CEAF – Specialized Pharmaceutical Care Component)  | (CEAF – Specialized Pharmaceutical Care Component) |
|                                                                                | Provision of contraceptive methods to the fertile population. Includes oral and injectable contraceptives, | Contraceptive                                     |
|                                                                                | intrauterine device (IUD), and diaphragm                                                               | For gynecological disorder                        |
| Política Nacional para a Prevenção e Controle do Cancro na Rede de Atenção à Saúde das Pessoas com Doenças Crônicas (National Policy for Cancer Prevention and Control in the Health Care Network for Chronic Diseases) | Access to chemotherapy. With the emergence of oral chemotherapy drugs, the high complexity oncology centers  | For cancer                                        |
|                                                                                | (Centros de Alta Complexidade em Oncologia, CACON) and the high complexity oncology care units (Unidades de Assistência em Alta Complexidade em Oncologia, UNACON) started dispensing chemotherapy drugs for use by patients at home. The Ministry of Health performs centralized purchase of some antineoplastic drugs aiming to reduce the cost of treatment in SUS, and increase the population’s access to treatment |                                                                             |
| Política de Saúde Mental (Mental Health Policy)                                | Access to medicines for mental suffering or disorder. The Relação Nacional de Medicamentos Essenciais (Rename – National List of Essential Medicines) includes medicines for the treatment of several health conditions in this field: anxiolytics, antidepressants, and antipsychotics, among others | For depression (antidepressant)                   |
|                                                                                | for the treatment of mental suffering or disorder. The Relação Nacional de Medicamentos Essenciais (Rename – National List of Essential Medicines) includes medicines for the treatment of several health conditions in this field: anxiolytics, antidepressants, and antipsychotics, among others | For stress (tranquilizer)                         |
|                                                                                | for the treatment of mental suffering or disorder. The Relação Nacional de Medicamentos Essenciais (Rename – National List of Essential Medicines) includes medicines for the treatment of several health conditions in this field: anxiolytics, antidepressants, and antipsychotics, among others | For the nervous system                            |
|                                                                                | for the treatment of mental suffering or disorder. The Relação Nacional de Medicamentos Essenciais (Rename – National List of Essential Medicines) includes medicines for the treatment of several health conditions in this field: anxiolytics, antidepressants, and antipsychotics, among others | For stress (tranquilizer)                         |
|                                                                                | for the treatment of mental suffering or disorder. The Relação Nacional de Medicamentos Essenciais (Rename – National List of Essential Medicines) includes medicines for the treatment of several health conditions in this field: anxiolytics, antidepressants, and antipsychotics, among others | For the nervous system                            |
| Política Nacional de Transplantes de Órgãos e Tecidos (National Policy for Organ and Tissue Transplant) | There is no formal policy with this denomination There is, however, a National Transplant System, in addition to clinical protocols and therapeutic guidelines that establish the use of immunosuppressants and other drugs in the treatment of transplanted patients. Medicines listed in the protocols are part of the Rename | For depression (antidepressant)                   |
|                                                                                | for the treatment of transplant patients. Medicines listed in the protocols are part of the Rename | For stress (tranquilizer)                         |
|                                                                                | for the treatment of transplant patients. Medicines listed in the protocols are part of the Rename | For the nervous system                            |
| Política Nacional de Atenção Integral da Saúde do Homem (National Policy for Men’s Healthcare) | Its guidelines include, among others, the treatment of male diseases and illnesses. The Rename includes drugs for the treatment of benign prostatic hyperplasia | For prostate and urinary tract                    |
|                                                                                | for the treatment of benign prostatic hyperplasia | For asthma and bronchitis                         |
|                                                                                | for the treatment of benign prostatic hyperplasia | For diabetes                                      |
|                                                                                | for the treatment of benign prostatic hyperplasia | For bones and joints                              |
|                                                                                | for the treatment of benign prostatic hyperplasia | For high blood pressure (antihypertensive)        |
|                                                                                | for the treatment of benign prostatic hyperplasia | For lowering cholesterol or triglycerides         |
| Programa Farmácia Popular do Brasil (Popular Pharmacy Program in Brazil)       | Dispensing by private pharmacies, upon users’ co-payment, of a list of drugs used to treat dyslipidemia, osteoporosis, glaucoma, rhinitis, and Parkinson’s disease, as well as contraceptives, and geriatric diapers. Free dispensing to the patient of Programa Farmácia Popular do Brasil (Popular Pharmacy Program in Brazil) used in the treatment of hypertension, diabetes, and asthma | For combating smoking                              |
|                                                                                | Programa Farmácia Popular do Brasil (Popular Pharmacy Program in Brazil) used in the treatment of hypertension, diabetes, and asthma | For Aids                                          |
|                                                                                | Access to vaccines and sera | For travelers’ vaccines                            |
|                                                                                | Access to vaccines and sera | For infectious and endemic diseases                |
| Programas Estratégicos de Saúde (Strategic Health Programs)                    | There is no formal program with this denomination. It includes a set of health programs, such as control of tuberculosis, leprosy, focal endemics, flu (influenza), as well as prevention of nutritional deficiencies, and the blood and blood products program | For infectious and endemic diseases                |

POF: Pesquisa de Orçamentos Familiares; STDs: sexually transmitted diseases.
In the analysis by age group, non-monetary acquisition of medicines is higher among the elderly, where most subjects regularly consume medicines. Also, 39.2% of the non-monetary acquisitions are concentrated in the > 60 year-old groups. In the 70–74 years-old age group, 77.3% reported monetary and/or non-monetary consumption of medicines in the month prior to the survey.

Considering both monetary and non-monetary acquisitions recorded in the POF, medicines related to specific PC programs accounted for 41.4% of the total consumption value, but concentrate 67.8% of the non-monetary acquisitions. Among all medicines with specific guarantees of access with reported consumption, 33.6% were non-monetary acquisitions. In other words, even though most of the medicines obtained by non-monetary means are related to PC programs, non-monetary acquisitions represent only one-third of their total consumption.

Source: data from the Pesquisa de Orçamentos Familiares (POF), 2017–2018.

Figure. Mode of acquisition of medicines in the last 30-days (% in total consumption) according to age and income groups. Brazil, 2017–2018.

https://doi.org/10.11606/s1518-8787.2022056003898
Over half of pharmaceutical products listed in the POF (58.6%) are not related to any health program or policy. In this group, 11.3% of the consumption value refers to non-monetary acquisitions.

Table 1 presents average monthly values for monetary and non-monetary acquisitions for the selected access-related POF pharmaceutical products, in addition to monetary acquisitions (value and subjects) as a share of total consumption. For hypertension, cholesterol, prostate, and urinary tract pharmaceuticals, the average monthly value of monetary acquisitions was higher than for non-monetary acquisitions. For eye conditions the opposite occurred, with a higher average value for non-monetary acquisitions. For the other products, price differences (average value per purchase) were within the confidence intervals.

Ranking medicines according to monetary acquisitions as a percentage of the total consumption evidences a relationship between this percentage and the average monthly value per purchase. The share of monetary acquisitions is usually higher for the lower-priced medicines.

Considering expenditures (values) reported for all the pharmaceutical products listed in the POF, 20.5% referred to non-monetary acquisitions. Although most of the pharmaceutical consumption in Brazil relies on out of pocket payment (OOP) by households (monetary acquisition), there are items which are mainly obtained by non-monetary means. This is the case of vaccines (83.3% not depending on OOP). Table 2 shows the estimated values for monthly acquisitions and the number of subjects obtaining medicines through monetary and non-monetary acquisition according to policy and POF type of pharmaceutical product.

In addition to vaccines, cancer drugs were also mainly obtained by non-monetary means (70.3%). Two of the three classes of medicines for chronic diseases dispensed in SUS units and by the Programa Farmácia Popular (Popular Pharmacy Program) stand out: medicines for diabetes and for hypertension. The POF does not specifically discriminate data for asthma medicines, another item in the Programa Farmácia Popular for which no copayment is required. However, medicines for “asthma and bronchitis” in the POF have 29.2% of their values in non-monetary acquisitions.

Table 1. Average monthly values (R$) for monetary and non-monetary acquisitions and share (95%CI) of monetary acquisitions (values and persons) in total expenditure for selected pharmaceuticals with SUS specific policy-related guarantees.

| Pharmaceutical product                  | Average monthly monetary acquisition (R$) | Average monthly non-monetary acquisition (R$) | Monetary acquisitions as a share (%) of total expenditure | Subjects (%) reporting monetary acquisition |
|----------------------------------------|------------------------------------------|------------------------------------------------|--------------------------------------------------------|---------------------------------------------|
| Vaccines                               | 181.9 (89.5–274.3)                       | 143.2 (109.0–177.4)                           | 16.7 (6.5–26.9)                                          | 13.6 (7.4–19.8)                             |
| For cancer                             | 234.7 (160.5–308.8)                      | 307.4 (174.6–440.2)                           | 29.7 (17.1–42.4)                                         | 36.2 (24.9–47.5)                            |
| For diabetes                           | 96.1 (89.5–102.8)                        | 70.9 (64.1–77.6)                              | 52.1 (48.5–55.7)                                         | 45.8 (43.9–47.7)                            |
| For infectious and endemic diseases    | 147.1 (124.3–169.9)                      | 207.2 (162.6–251.8)                           | 58.5 (46.9–70.0)                                         | 69.5 (60.6–78.4)                            |
| For high blood pressure (antihypertensive) | 47.9 (46.3–49.6)                       | 34.8 (33.3–36.3)                              | 64.1 (62.4–65.9)                                         | 57.7 (56.4–59.0)                            |
| For lowering cholesterol or triglycerides | 48.6 (46.2–51.0)                       | 39.3 (35.1–43.5)                              | 68.7 (65.2–72.2)                                         | 64.7 (62.3–67.0)                            |
| For the nervous system                 | 117.9 (109.3–126.5)                      | 116.8 (102.0–131.6)                           | 70.0 (66.1–73.8)                                         | 72.6 (70.2–75.0)                            |
| For asthma and bronchitis             | 93.5 (84.1–103.0)                        | 98.8 (84.2–113.5)                             | 70.8 (64.5–77.1)                                         | 74.1 (68.9–79.4)                            |
| For depression (antidepressant)        | 110.7 (103.3–118.1)                      | 95.2 (83.4–106.9)                             | 74.3 (70.9–77.8)                                         | 72.6 (70.3–74.9)                            |
| Condom and intimate gels               | 15.6 (10.3–21.0)                         | 13.8 (11.8–15.9)                              | 75.3 (67.5–83.1)                                         | 73.3 (68.8–77.8)                            |
| For stress (tranquilizer)             | 59.9 (56.2–63.7)                         | 52.5 (44.0–60.9)                              | 77.4 (74.0–80.9)                                         | 76.0 (73.6–78.4)                            |
| For bones and joints                  | 97.8 (90.0–105.6)                        | 93.4 (79.5–107.3)                             | 81.8 (78.0–85.6)                                         | 82.3 (79.3–85.2)                            |
| For eye disorders (ophthalmology)      | 65.2 (60.7–69.9)                         | 89.6 (73.0–106.2)                             | 86.0 (83.0–89.1)                                         | 90.7 (89.1–92.2)                            |
| For gynecological disorder            | 58.6 (51.7–65.5)                         | 54.3 (49.4–79.2)                              | 88.4 (82.1–94.7)                                         | 87.6 (84.4–90.9)                            |
| For prostate and urinary tract        | 85.5 (78.8–92.2)                         | 57.8 (46.2–69.5)                              | 89.3 (85.6–93.0)                                         | 85.0 (80.6–89.4)                            |
| Contraceptive                         | 23.5 (22.6–24.5)                         | 20.2 (18.4–21.9)                              | 90.3 (89.0–91.6)                                         | 89.0 (87.8–90.1)                            |

Source: data from the Pesquisa de Orçamentos Familiares (POF), 2017–2018.
95%CI: confidence interval of 95%; SUS: Sistema Único de Saúde (National Health System).
Note: medications with small sample size or non-significant results were not included.

https://doi.org/10.11606/s1518-8787.2022056003898
The POF did not report monetary acquisitions for Aids medicines, as they are not sold at commercial pharmacies. Thus, there is no price reference for respondents in their value estimates of non-monetary acquisitions. Small samples reporting consumption of medicines for Aids, autism, alcoholism, smoking and immunosuppressants preclude a robust estimate of monthly averages for these pharmaceuticals.

Non-monetary acquisitions also had significant shares in medicines for: infectious or endemic diseases (41.5%); cholesterol-lowering (31.3%); and nervous system (30%). Contraceptives (9.7%); prostate and urinary tract medicines (10.7%); medicines for gynecological problems (11.6%); and for eye conditions (14%) hold the smallest shares for non-monetary acquisitions in total consumption.

Table 3 shows the percentages of non-monetary acquisitions for medicines related to each health program or policy by age and income groups.

For most programs and policies with specific medicine guarantees, differences between age groups were not significant. Sample size did not allow disaggregation by age and income in some cases.

Table 2. Monthly monetary and non-monetary consumption of medicines with specific guarantees provided, in amount (R$ million) and number of subjects obtaining them (in thousands) (95%CI).

| Policies and programs / POF pharmaceutical products | Monetary acquisitions (million R$) | Non-monetary acquisitions (million R$) | Monetary acquisitions (in thousand inhabitants) | Non-monetary acquisitions (in thousand inhabitants) |
|-----------------------------------------------------|----------------------------------|---------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Política Nacional de Atenção em Oftalmologia (National Eye Care Policy) | 168.2 (151.7–184.7) | 27.4 (20.9–33.8) | 2,578.4 (2,397.8–2,759.0) | 305.4 (250.3–360.6) |
| For eye disorders (ophthalmology) | 168.2 (151.7–184.7) | 27.4 (20.9–33.8) | 2,578.4 (2,397.8–2,759.0) | 305.4 (250.3–360.6) |
| Política Nacional de Atenção Integral à Saúde da Mulher (National Policy for Women's Healthcare) | 192.0 (179.9–204.1) | 21.6 (17.9–25.3) | 7,138.0 (6,792.0–7,484.0) | 910.2 (816.4–1,003.9) |
| Contraceptive | 153.9 (143.8–164.1) | 16.6 (14.3–18.9) | 6,543.2 (6,213.9–6,872.4) | 821.4 (730.5–912.3) |
| For gynecological disorder | 38.1 (31.8–44.3) | 5.0 (2.1–8.0) | 650.1 (573.2–727.0) | 92.5 (66.8–118.1) |
| Política Nacional de Atenção Oncológica (Brazilian Policy on Oncology Care) | 18.8 (10.5–27.1) | 44.4 (25.9–63.0) | 80.1 (54.8–105.6) | 144.6 (92.8–196.3) |
| For cancer | 18.8 (10.5–27.1) | 44.4 (25.9–63.0) | 80.1 (54.8–105.5) | 144.6 (92.8–196.3) |
| Política Nacional de Saúde Mental (Brazilian Mental Health Policy) | 825.5 (777.0–874.1) | 299.3 (268.0–330.6) | 7,858.0 (7,527.0–8,190.0) | 2,982.9 (2,792.5–3,173.4) |
| For depression (antidepressant) | 331.1 (300.5–361.7) | 114.3 (96.7–132.0) | 2,991.4 (2,801.3–3,182.1) | 1,201.3 (1,091.3–1,311.3) |
| For stress (tranquilizer) | 194.1 (176.7–216.1) | 56.6 (45.3–67.8) | 3,239.2 (3,038.9–3,439.6) | 1,078.1 (957.9–1,198.4) |
| For the nervous system | 299.1 (270.3–327.6) | 128.4 (107.1–149.7) | 2,537.3 (2,364.2–2,710.5) | 999.6 (984.4–2,147.4) |
| Política Nacional de Atenção Integral da Saúde do Homem (National Policy for Men's Healthcare) | 48.9 (42.1–55.8) | 5.9 (3.8–8.0) | 572.2 (501.5–642.9) | 101.5 (69.0–134.0) |
| For prostate and urinary tract | 48.9 (42.1–55.8) | 5.9 (3.8–8.0) | 572.2 (501.5–642.9) | 101.5 (69.0–134.0) |
| Programa Farmácia Popular do Brasil (Popular Pharmacy Program in Brazil) | 1,336.3 (1,275.0–1,397.5) | 796.1 (748.2–844.0) | 18,374.0 (17,841.0–18,908.0) | 13,233.0 (12,775.5–13,690.5) |
| For asthma and bronchitis | 60.8 (51.2–70.4) | 25.1 (18.6–31.5) | 650 (569.4–730.5) | 253.5 (195.2–311.8) |
| For diabetes | 328.5 (298–359.1) | 302.2 (268.4–336.0) | 3,418 (3,225.7–3,610.3) | 4,264 (4,043.3–4,484.7) |
| For bones and joints | 123.2 (107.6–138.7) | 27.5 (21.2–33.7) | 1,260 (1,139–1,381) | 294.3 (263.2–345) |
| For high blood pressure (antihypertensive) | 639.8 (609.5–670.1) | 357.7 (336.2–379.2) | 13,352.7 (12,923.5–13,781.9) | 10,277.5 (9,874.6–10,680.4) |
| For lowering cholesterol or triglycerides | 184 (168.9–199.1) | 83.7 (71.5–95.9) | 3,782 (3,541.5–4,024.2) | 2,129.3 (1,960.2–2,298.5) |
| Programa Nacional de DST/AIDS (National STDs/AIDS Program) | 13.6 (8.6–18.6) | 56.4 (24.8–88.0) | 873.4 (740.4–1,006.5) | 360.0 (293.9–426.1) |
| Condom and intimate lubricant | 13.6 (8.6–18.6) | 4.5 (3.5–5.4) | 873.4 (740.4–1,006.5) | 323.3 (260.8–385.8) |
| Programa Nacional de Imunizações (National Immunization Program) | 8.8 (3.0–14.5) | 43.8 (28.8–58.7) | 48.2 (24.6–71.8) | 305.6 (231.3–379.9) |
| Vaccines | 8.8 (3.0–14.5) | 43.8 (28.8–58.7) | 48.2 (24.6–71.8) | 305.6 (231.3–379.9) |
| Programas Estratégicos de Saúde (Strategic Health Programs) | 29.6 (21.4–37.8) | 21.1 (12.3–29.8) | 201.3 (152.0–250.7) | 101.6 (67.7–135.5) |
| For infectious and endemic diseases | 29.6 (21.4–37.8) | 21.1 (12.3–29.8) | 201.3 (152.0–250.7) | 101.6 (67.7–135.5) |

Source: data from the Pesquisa de Orçamentos Familiares (POF), 2017–2018.
95%CI: confidence interval of 95%; STDs: sexually transmitted diseases.
Note: medicines and programs with small sample size or non-significant results were not included.

https://doi.org/10.11606/s1518-8787.2022056003898
Income groups in the 0-15 MWs range reported higher percentages of non-monetary acquisitions for the programs studied, with the exception of medicines related to the Política Nacional de Atenção em Oftalmologia (National Eye Care Policy), with a confidence interval too wide to support this conclusion. Households with incomes > 15 MWs showed lower shares of non-monetary acquisitions for medicines (Table 3).

**DISCUSSION**

Non-monetary acquisition by households accounted for 20.5% of the total value of pharmaceutical consumption in the POF. The highest shares for non-monetary acquisitions were reported by households in the < 10 MW income groups and for older age groups. The share of public funding in pharmaceutical consumption is notoriously low in Brazil, far below the OECD average of 58%.

In the Conta-Satélite de Saúde (Brazilian Health Satellite Accounts), an IBGE publication with aggregate data for health-related goods and services, non-monetary medicine consumption by Brazilian households represented 7.5% of total pharmaceutical consumption. The main reason for the difference in non-monetary consumption between the POF and the Conta-Satélite concerns prices and the type of pharmaceutical purchased by the government. The government provides medicines based on medical prescriptions and rational use. It also buys in larger scale and pays lower prices comparatively to households, as it uses the Preços Máximos de Venda Governamental (Government Maximum Sales Prices), which are below market prices in some cases. Thus, with equal resources, the government will buy more units of pharmaceuticals than households. On assuming similar prices for monetary and non-monetary acquisitions, one could say that the POF’s percentage for non-monetary acquisitions is lower than that reported in the Conta-Satélite.

### Table 3. Non-monetary acquisitions as shares (%) of consumption for medicines with specific guarantees of access, according to policy or program, age and income (in minimum wages) groups (95%CI).

| Income groups | Programa Nacional de DST/aids (National STDs/Aids Program) | Programa Farmácia Popular no Brasil (Popular Pharmacy Program in Brazil) | Programa Nacional de Imunizações (National Immunization Program) | Política Nacional de Atenção em Oftalmologia (National Eye Care Policy) | Política Nacional de Saúde Mental (Brazilian Mental Health Policy) | Política Nacional de Atenção Integral à Saúde da Mulher (National Policy for Women’s Healthcare) |
|---------------|-----------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| < 20          | 41.3 (28.2–55.7)                                          | 38.5 (26.6–51.9)                                             | 82.9 (61.9–93.5)                                              | 18.6 (7.5–39.1)                                              | 36.8 (28.4–46.1)                                              | 14.3 (10.9–18.5)                                              |
| 20–29         | 30.6 (23.6–38.6)                                          | 29.9 (24.2–36.2)                                             | 81.8 (63.0–92.2)                                              | 7.7 (3.2–17.1)                                               | 28.9 (23.0–35.5)                                              | 11.4 (9.7–13.4)                                               |
| 30–39         | 20.9 (15.0–28.3)                                          | 33.7 (30.1–37.6)                                             | 88.6 (74.4–95.4)                                              | 8.9 (4.5–16.7)                                               | 25.2 (21.7–29.0)                                              | 10.7 (8.9–12.8)                                               |
| 40–49         | 23.3 (14.8–34.7)                                          | 41.8 (39.3–44.3)                                             | 83.9 (64.1–93.8)                                              | 5.9 (3.3–10.2)                                               | 29.9 (26.6–33.5)                                              | 9.8 (7.5–12.7)                                                |
| 50–59         | 55.2 (33.4–75.2)                                          | 47.3 (45.2–49.3)                                             | 79.3 (54.2–92.6)                                              | 6.8 (4.5–10.3)                                               | 31.5 (28.5–34.6)                                              | 15.2 (9.7–23.1)                                               |
| 60–69         | 54.6 (22.9–82.9)                                          | 48.8 (46.9–50.8)                                             | 95.2 (69.5–99.4)                                              | 15.2 (10.9–20.7)                                             | 29.5 (25.9–33.3)                                              | 9.8 (2.7–30.1)                                                |
| 70–79         | 9.7 (0.2–82.8)                                            | 48.9 (46.6–51.2)                                             | 100.0 (NA)                                                    | 15.4 (11.0–21.0)                                             | 26.6 (22.5–31.2)                                              | 25.1 (5.5–65.8)                                               |
| > 79          | NA                                                        | 41.8 (38.3–45.4)                                             | 100.0 (NA)                                                    | 9.5 (4.9–17.4)                                               | 18.9 (14.1–24.9)                                              | 22.0 (3.2–70.9)                                               |

Source: data from the Pesquisa de Orçamentos Familiares (POF), 2017–2018.

95%CI: confidence interval of 95%; NA: not available; STDs: sexually transmitted diseases.

Note: health programs with small sample size or non-significant results were not included.
acquisitions provides a fairer description of shares in terms of physical quantities than values obtained from the Conta-Satélite24.

The distinctive access guarantees contained in some specific health policies and programs (such as the Programa Nacional de Imunizações [Brazilian Immunization Program] and in the Programa Farmácia Popular [Popular Pharmacy Program]) have apparently secured greater non-monetary access than the list of general guarantees in the PNAF. Brazil seems thus to evidence similarities to other developing countries, which tend to concentrate public funding for PC in specific niches of populations or diseases5.

Even specific guarantees of access to medicines may lead to very different coverages. Among the medicines with the highest shares of non-monetary acquisition, vaccines (83.3%), and cancer drugs (70.3%) stand out. On the other end, contraceptives (9.7%), medicines for prostate and the urinary tract (10.7%), for gynecological problems (11.6%), and for eye conditions (14%) show low percentages of non-monetary obtention.

Non-monetary access to medicines for hypertension and diabetes via the Programa Farmácia Popular prevented hospitalizations in the SUS, and deaths related to these diseases in the municipalities hosting the program25. The free availability of medicines in Programa Farmácia Popular and the end of copayment increased their use. This suggests that, for many people, price is a barrier to access, even if products are dispensed in pharmacies of the SUS health units26,27.

Lower income groups obtain medicines by non-monetary means more often than higher income groups. As price is a more frequent barrier to access26 for them, obtaining medicines at no cost prevents the worsening of health status, potential hospitalizations and early death due to interruptions in treatment of previously diagnosed chronic diseases25.

This implies that the decrease in public funding for medicines reported in administrative records since 2016 may have grave effects both on population health and on expenditure on services, overloading the hospital network with preventable cases25.

Women’s care was the PC-sponsored program with lowest coverage. This was a surprising finding considering the prominence of this policy segment, related to goals 3 and 5 of the Sustainable Development Goals (SDG)28. Policies on men’s health care, eye care, and tobacco control also recorded low shares for non-monetary acquisition of medicines. Among the more recent policies, OOP values required to buy some medications with low prices in private pharmacies, such as contraceptives, may be one of the reasons for the low coverage seen for these policies. High prices and low barriers to access in SUS probably act as incentives for seeking medicines through public provision. Complexity in procedures to obtain these medicines may discourage this demand, especially burdening those with lower income. This suggests a need to simplify the procedures for medicine obtention for products reporting low shares of non-monetary acquisitions, as in the case of contraceptives.

The good coverage for the so-called ‘poverty medicines’ (vaccines and endemic diseases) draws attention. These products focus on communicable diseases and imply the oldest specific guarantees in PC, as the Programa Nacional de Imunizações preceded the PNAF29.

This study has some limitations. For the very advanced ages, small sample size leads to frail estimates, given data variability. For less-used medicines (such as for smoking or cancer), small samples produce large variances preventing meaningful analyses by age or income groups.

There are also differences between POF results for non-monetary acquisition of medicines and government administrative records for expenditures in specific programs, such as for Aids. This limitation of the database reflects the estimation of non-monetary acquisition values by POF respondents and the small sample sizes for medicines used by a small part of the population.

The survey does not record medicine acquisition by under-10-year-olds. It also reports acquisition and not actual use of the medication. So one can presume that the acquisitions
made for use of younger age groups are largely made by their parents and recorded as parental acquisitions. This leads to potential overestimation of consumption for groups in charge of children or minors.

The distribution of free samples of medicines and, since 2014, the provision of oral antineoplastics and medicines for chemotherapy side effects by health plans need to be acknowledged, as they may account for part of the non-monetary acquisitions. It would be thus incorrect to suppose that all non-monetary medicine acquisitions in the POF reflect SUS funding.

Estimation of values for non-monetary acquisitions by POF respondents has generated some mistrust regarding data, and could be considered a limitation. However, on comparing average monthly values for monetary and non-monetary acquisitions of the selected pharmaceuticals in our study no substantial differences were found. This strengthens the case for the use of these data. The use of POF non-monetary acquisition data is one of the positive contributions of this article to the study of PC coverage.

The policies and programs highlighted in this study provide specific medicines to their beneficiaries. It should be remembered, however, that the right to comprehensive therapeutic care is an integral part of the right to health. To ensure it, central and sub-national governments in Brazil have implemented several measures to strengthen PC in the SUS. A large network of public pharmacies is responsible for delivering PC throughout the country. However, the low availability of medicines in these pharmacies may partly explain the high percentage of monetary acquisitions for highly prevalent diseases, even when additional guarantees defined in specific policies and programs are in place. This suggests the existence of barriers to access to these products in the SUS.

The results of this article suggest the need to strengthen and expand PC policies. They have mainly benefited groups with lower income or higher age-related consumption. Data on monetary and non-monetary medicine acquisitions provided in the POF, albeit indirectly, help to describe the scope of these policies regarding access to medications.

REFERENCES

1. Belloni A, Morgan D, Paris V. Pharmaceutical expenditure and policies: past trends and future challenges. Paris (FR): OECD; 2016. (OECD Health Working Papers; nº 87). https://doi.org/10.1787/5jm0q1f4cdq7-en
2. Instituto Brasileiro de Geografia e Estatística. Conta-satélite de saúde: Brasil: 2010-2017. Rio de Janeiro: IBGE; 2019 [cited 2021 Feb 17]. Available from: http://informe.ensp.fiocruz.br/assets/anos/2019/5/10/contasatelite_gourmet_pdf.pdf
3. Boing AC, Bertoldi AD, Posenato LG, Peres KG. Influência dos gastos em saúde no empobrecimento de domicílios no Brasil. RevSaude Publica. 2014;48(5):797-807. https://doi.org/10.1590/S0034-8910.2014048005113
4. Maniadakis N, Kourlaba G, Shen J, Holtorf A. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status. BMC Health Serv Res. 2017;17:371. https://doi.org/10.1186/s12913-017-2304-2
5. Dias LLS, Santos MAB, Pinto CDBS. Regulação contemporânea de preços de medicamentos no Brasil - uma análise crítica. Saude Debate;43(121):543-58. https://doi.org/10.1590/0103-1104201912120
6. Vogler S, Haasis MA, Dedet G, Lam J, Pedersen HB. Medicines reimbursement policies in Europe. Copenhagen (DK): WHO Regional Office for Europe; 2018 [cited 2021 May 21]. Available from: https://www.euro.who.int/__data/assets/pdf_file/0011/376625/pharmaceutical-reimbursement-eng.pdf
7. Barnieh L, Clement F, Harris A, Blom M, Donaldson C, Klarenbach S, et al. A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the Organisation for Economic Co-Operation and Development. PLoS One. 2014;9(3):e90434. https://doi.org/10.1371/journal.pone.0090434
8. Ministério da Saúde (BR). Portaria Nº 3.916, de 30 de outubro de 1998. Aprova a Política Nacional de Medicamentos. Brasília, DF; 1998 [citado 2021 Feb 17]. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/gm/1998/prt3916_30_10_1998.html

9. Ministério da Saúde (BR), Conselho Nacional de Saúde. Resolução Nº 338, de 6 de maio de 2004. Aprova a Política Nacional de Assistência Farmacêutica. Brasília, DF; CNS; 2004 [citado 2021 Feb 17]. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/cms/2004/res0338_06_05_2004.html

10. Santos-Pinto CDB, Ventura M, Pepe VLE, Osorio-de-Castro CGS. Novos delineamentos da Assistência Farmacêutica frente à regulamentação da Lei Orgânica da Saúde. CadSaude Publica. 2013;29(6):1056-8. https://doi.org/10.1590/S0102-311X2013000600002

11. Instituto Brasileiro de Geografia e Estatística, Diretoria de Pesquisas, Coordenação de Trabalho e Rendimento. Pesquisa de Orçamentos Familiares: primeiros resultados: 2017-2018. Rio de Janeiro: IBGE; 2019 [citado 2021 Feb 17]. Available from: https://biblioteca.ibge.gov.br/visualizacao/livros/liv101670.pdf

12. Lumley T. The Analysis of Complex Survey Samples. Wien (AT): CRAN; 2020 [citado 2021 May 21]. Available from: https://cran.r-project.org/web/packages/survey/survey.pdf

13. Ministério da Saúde (BR). Portaria de Consolidação Nº 2, de 28 de setembro de 2017. Consolidação das normas sobre as políticas nacionais de saúde do Sistema Único de Saúde. Brasília, DF; 2017 [citado 2021 Mar 11]. Available from: http://www.cvs.saude.sp.gov.br/zip/U_PRC-MS-GM-2_280917.pdf

14. Ministério da Saúde (BR), Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde, Departamento de Assistência Farmacêutica e Insumos Estratégicos em Saúde. Relação Nacional de Medicamentos Essenciais 2020. Brasília, DF; 2020 [citado 2021 Mar 11]. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/relacao_medicamentos_rename_2020.pdf

15. Ministério da Saúde (BR), Secretaria de Atenção à Saúde, Departamento de Regulação, Avaliação e Controle, Coordenação-Geral de Sistemas de Informação. Manual de bases técnicas da oncologia - SIA/SUS. 21. ed. Brasília, DF; 2015. [citado 2021 Mar 11]. Available from: https://portalarquivos.saude.gov.br/images/pdf/2015/outubro/16/Manual-Oncologia-21-edi---o-14-09-2015.pdf

16. Ministério da Saúde (BR). Portaria de Consolidação Nº 3, de 28 de setembro de 2017. Consolidação das normas sobre as redes do Sistema Único de Saúde. Brasília, DF; 2017 [citado 2021 Mar 11]. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2017/prc0003_03_10_2017.html

17. Ministério da Saúde (BR). Portaria de Consolidação Nº 4, de 28 de setembro de 2017. Consolidação das normas sobre os sistemas e os subsistemas do Sistema Único de Saúde. Brasília, DF; 2017 [citado 2021 Mar 11]. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2017/MatrizesConsolidacao/Matriz-4-Sistemas.html

18. Brasil. Decreto Nº 5.090, de 20 de maio de 2004. Regulamenta a Lei no 10.858, de 13 de abril de 2004, e institui o programa “Farmácia Popular do Brasil”, e dá outras providências. Brasília, DF; 2004 [citado 2021 Mar 11]. Available from: http://www.planalto.gov.br/ccivil_03/ato2004-2006/2004/decreto/d5090.htm

19. Ministério da Saúde (BR). Farmácia Popular. Brasília, DF; 2021 [citado 2021 Mar 11]. Available from: https://antigo.saude.gov.br/acoes-e-programas/farmaciapopular

20. Brasil. Lei Nº 9.313, de 13 de novembro de 1996. Dispõe sobre a distribuição gratuita de medicamentos aos portadores do HIV e doentes de AIDS. Brasília, DF; 1996 [citado 2021 Mar 11]. Available from: https://www.planalto.gov.br/ccivil_03/lei/9313.htm

21. Ministério da Saúde (BR). Programa Nacional de Imunizações: 30 anos. Brasília, DF; 2003 [citado 2021 Mar 11]. (Série C. Projetos e Programas e Relatórios). Available from: https://bvsms.saude.gov.br/bvs/publicacoes/livro_30_anos_pni.pdf

22. Secretaria de Estado da Saúde do Espírito Santo. Programas do Componente Estratégico. Vitória; SD [citado 2021 Mar 11]. Available from: https://farmaciadecidadade.es.gov.br/programas-do-componente-estrategico

23. Organisation for Economic Co-operation and Development. Health at a glance: OECD indicators 2019. Paris (FR): OECD; 2019. https://doi.org/10.1787/4dd505cc-0-en

24. Vieira FS, Santos MAB. O setor farmacêutico no Brasil sob as lentes da conta-satélite de saúde. Brasília, DF: Ipea; 2020 [citado 2021 May 6]. (Texto para Discussão; nº 2615). Available from: http://repositorio.ipea.gov.br/bitstream/11058/10328/1/td_2615.pdf
25. Almeida ATC, Sá EB, Vieira FS, Benevides RPS. Impacts of a Brazilian pharmaceutical program on the health of chronic patients. RevSaude Publica. 2019;53:20.https://doi.org/10.11606/S1518-8787.2019053000733

26. Emmerick ICM, Campos MR, Luiza VL, Bertoldi AD, Ross-Degnan D. Retrospective interrupted time series examining hypertension and diabetes medicines usage following changes in patient cost sharing in the ‘Farmácia Popular’ programme in Brazil. BMJ Open. 2017;7(11):e017308.https://doi.org/10.1136/bmjopen-2017-017308

27. Almeida ATC, Vieira FS. Copagamento dos usuários no programa Farmácia Popular do Brasil: um estudo exploratório da rede conveniada. Brasília, DF: Ipea; 2020 [cited 2021 Feb 17]. (Texto para Discussão; nº 2585). Available from: http://repositorio.ipea.gov.br/bitstream/11058/10218/1/tl_2585.pdf

28. World Health Organization. Sustainable Development Goals (SDGs). Geneva (CH): WHO; c2021 [cited 2021 May 21]. Available from: https://www.who.int/health-topics/sustainable-development-goals#tab=tab_3

29. Santana RS, Lupatini EO, Leite SN. Registro e incorporação de tecnologias no SUS: barreiras de acesso a medicamentos para doenças da pobreza? CiencSaudeColetiva. 2017;22(5):1417-28. https://doi.org/10.1590/1413-81232017225.32762016

30. Ministério da Saúde (BR). Agência Nacional de Vigilância Sanitária. Resolução-RDC Nº 60, de 26 de novembro de 2009. Dispõe sobre a produção, dispensação e controle de amostras grátis de medicamentos e dá outras providências. Brasília, DF: Anvisa; 2009 [cited 2021 May 21]. Available from: https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2009/rcd0060_26_11_2009.html

31. Brasil. Lei Nº 12.880 de 13 de novembro de 2013. Altera a Lei nº 9656 de 3 de junho de 1998, que dispõe sobre os planos e seguros privados de “assistência à saúde”, para incluir tratamentos entre as coberturas obrigatórias. Brasília, DF; 2013 [cited 2021 May 21]. Available from: https://presrepublica.jusbrasil.com.br/legislacao/112108327/lei-12880-13

32. Nascimento RCRM, Álvares J, Guerra Junior AA, Gomes IC, Costa EA, Leite SN, et al. Disponibilidade de medicamentos essenciais na atenção primária do Sistema Único de Saúde. RevSaude Publica. 2017; 51 Supl 2:10s.https://doi.org/10.11606/s1518-8787.2017051007062

Funding: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes - article publication fee).

Authors' Contribution: Study conception and planning: RMM, MABS, FSV and RTA. Data collection, analysis and interpretation: RMM, MABS, FSV, RTA. Manuscript elaboration or review: RMM, MABS, FSV, RTA. Final version approval: RMM, MABS, FSV, RTA. Public responsibility for the article's content: RMM, MABS, FSV, RTA.

Conflict of Interest: The authors declare there is no conflict of interest.